Understand the early stages of an infection remains essential for the search for vaccines and therapies. In this regard, the scientific journal mBIO recently published a study by researchers at Baylor College of Medicine. The research focuses on the development of a versatile human nasal organoid, a laboratory representation of the cells found in the nasal vestibule and nasal cavities. From the established model, the scientists reproduced the events following an infection natural virus.
An effective tool for evaluate therapeutic products
Thanks to the’human nose organoid, the team highlighted the differences between infection with SARS-CoV-2 and respiratory syncytial virus (RSV). The first is the virus responsible for Covid-19 and the second is responsible for a pediatric respiratory virus.
The model has also proven to be an effective tool for evaluate therapeutic products such as palivizumab. This monoclonal antibody has been approved by the FDA to prevent serious RSV disease in infants.
The researchers used the human nose organoid
To test the effectiveness of palivizumab, the researchers placed the therapeutic monoclonal antibody in a fluid-filled chamber. This process has created an environment where the therapeutic antibodies enter the bloodstream and ensure the protection of the respiratory tract againstRSV infection.
” In our model, palivizumab effectively prevented RSV infection. »
Avadhanula, co-director of the certified respiratory virus diagnostic laboratory
To study the interaction between the SARS-CoV-2 or RSV and the epithelium of the nose, the scientists in charge of the study simulated a natural infection. For this, they placed each virus separately on the aerial side of the culture plates. They then studied the changes taking place on the organoid of the nose.
” We observed divergent responses to SARS-CoV-2 and RSV infection. SARS-CoV-2 causes severe epithelial damage and minimal mucus secretion, but no response to interferons has been observed. In contrast, RSV induces profuse secretion of mucus and a profound response to interferons. »
Dr. Vasanthi Avadhanula, co-author of the study
In this study, the team described for the first time a non-invasive approachreproducible and reliable for establishing human nose organoids that allow long-term studies.